comparemela.com

Latest Breaking News On - Eigen campus - Page 9 : comparemela.com

DGAP-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Postal code: Acquisition/disposal of instruments Other reason: Legal entity: T. Rowe Price Group, Inc. City of registered office, country: Baltimore, Maryland, United States of America (USA) 4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3. 5. Date on which threshold was crossed or reached: 25 May 2021 (total of 7.a.) (total of 7.b.1 + 7.b.2) New a. Voting rights attached to shares (Sec. 33, 34 WpHG) ISIN Type of instrument Type of instrument 8. Information in relation to the person subject to the notification obligation

DGAP-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 25.05.2021 / 16:00 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS .

PRESS RELEASE: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Message : Required fields DGAP-News: Evotec SE / Key word(s): Miscellaneous Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 2021-04-19 / 08:31 The issuer is solely responsible for the content of this announcement. = . EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 . KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC . EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC ) . EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES

DGAP-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Postal code: X Other reason: Legal entity: T. Rowe Price International Funds, Inc. City of registered office, country: Baltimore, Maryland, United States of America (USA) 4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3. 5. Date on which threshold was crossed or reached: 06 Apr 2021 (total of 7.a.) (total of 7.b.1 + 7.b.2) New a. Voting rights attached to shares (Sec. 33, 34 WpHG) ISIN Type of instrument Type of instrument 8. Information in relation to the person subject to the notification obligation

DGAP-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Postal code: Acquisition/disposal of instruments X Legal entity: Morgan Stanley 4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3. 5. Date on which threshold was crossed or reached: 17 Feb 2021 (total of 7.a.) (total of 7.b.1 + 7.b.2) New a. Voting rights attached to shares (Sec. 33, 34 WpHG) ISIN Type of instrument at any time Type of instrument 8. Information in relation to the person subject to the notification obligation Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.